Kenji Higaki

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers

Mitsuya Itoh, Takayuki Iwamoto, Junji Matsuoka et al. · Breast Cancer Research and Treatment · 2013 · 104 citations

Mrna Expression, Breast Oncology, Medicine +11

Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study)

Tatsuo Akechi, Takuhiro Yamaguchi, Megumi Uchida et al. · Journal of Clinical Oncology · 2022 · 68 citations · Full text

Radiofrequency ablation of early breast cancer followed by delayed surgical resection – A promising alternative to breast-conserving surgery

Shoichiro Ohtani, Mariko Kochi, Mitsuya Ito et al. · The Breast · 2011 · 45 citations · Full text

Surgical Oncology, Breast Oncology, Rfa Session +18

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

Norikazu Masuda, Kenji Higaki, Toshimi Takano et al. · Cancer Chemotherapy and Pharmacology · 2014 · 36 citations

Preoperative Chemotherapy, Breast Oncology, Oncology +11